Loading...

2628: Fair Value Will Remain Steady As Profitability Outlook Is Tempered

Published
07 Nov 24
Updated
02 Dec 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
71.9%
7D
0.2%

Author's Valuation

HK$28.586.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 02 Dec 25

Fair value Increased 6.08%

2628: Earnings Outlook And Dividend Payout Will Support Balanced Shareholder Returns

Analysts have raised their price target for China Life Insurance from ¥26.94 to ¥28.58. They cite updates to their valuation model and reflect confidence in the company’s long-term outlook.

What's in the News

  • China Life Insurance provided earnings guidance for the first nine months of 2025. The company estimates net profit attributable to equity holders will rise 50% to 70% year-on-year, reaching RMB156,785 million to RMB177,689 million (Key Developments).
  • The company’s board will meet on October 30, 2025 to review and approve unaudited results for the nine months ended September 30, 2025 (Key Developments).
  • The company announced an interim dividend of RMB 0.238 per share (HKD 0.26024 per share) for the first half of 2025, with payment expected on November 21, 2025 (Key Developments).
  • At the annual general meeting on September 25, 2025, shareholders approved amendments to the company’s Articles of Association (Key Developments).

Valuation Changes

  • Fair Value: increased from ¥26.94 to ¥28.58. This reflects a modest upward revision in analysts' intrinsic valuation.
  • Discount Rate: remains unchanged at 7.02%. This indicates a consistent approach to risk and capital costs.
  • Revenue Growth: minimal change, holding steady at approximately 28.00% year-on-year.
  • Net Profit Margin: edged down slightly from 7.60% to 7.58%.
  • Future P/E: increased from 14.39x to 15.21x. This suggests stronger future growth expectations are now being priced into the stock.

Key Takeaways

  • Diversification into whole life and participating products may face challenges from shifting preferences and interest rate impacts on revenue growth.
  • Managing sales force transformation and comprehensive liability costs could strain operational efficiency, potentially affecting profitability and net margins.
  • Strong revenue growth, improved net margins via new business, increased productivity, substantial investment income, and high solvency indicate solid financial health and future earnings potential.

Catalysts

About China Life Insurance
    Operates as a life insurance company in the People’s Republic of China.
What are the underlying business or industry changes driving this perspective?
  • The company's shift towards a diversified product portfolio, including increased focus on whole life and participating products, indicates potential challenges in adapting to changing customer preferences and interest rate environments, which could impact revenue growth.
  • The need for substantial training and transformation of the large sales force may lead to increased operational costs and inefficiencies in the short term, potentially affecting net margins and earnings.
  • The rapid rebound of the stock market has significantly boosted investment income, but future market volatility poses a risk to sustaining this growth, potentially impacting future earnings stability.
  • The company's strategic focus on managing the comprehensive liability cost to ensure long-term sustainability requires careful balancing, which, if not managed well, could affect profitability margins.
  • As interest rates stabilize, the company acknowledges potential challenges in maintaining the net investment return rate, which may not align with optimistic long-term investment assumptions, potentially leading to reassessments that could impact future net margins and earnings growth.

China Life Insurance Earnings and Revenue Growth

China Life Insurance Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming China Life Insurance's revenue will grow by 33.5% annually over the next 3 years.
  • Analysts assume that profit margins will shrink from 34.9% today to 9.1% in 3 years time.
  • Analysts expect earnings to reach CN¥67.9 billion (and earnings per share of CN¥2.49) by about September 2028, down from CN¥109.6 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CN¥118.5 billion in earnings, and the most bearish expecting CN¥40.2 billion.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 11.0x on those 2028 earnings, up from 5.5x today. This future PE is greater than the current PE for the US Insurance industry at 8.5x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.89%, as per the Simply Wall St company report.

China Life Insurance Future Earnings Per Share Growth

China Life Insurance Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • The company achieved record high gross written premiums, totaling RMB 608.2 billion, with an increase of 5.1% year-on-year. This indicates strong revenue growth and suggests potential for sustained earnings growth in the future.
  • The value of new business maintained rapid growth, increasing by 25.1% compared to restated results from 2023. This strong growth in new business value signifies potential for improved net margins and earnings.
  • The size of the sales force was stabilized, with a focus on improving sales force quality and productivity, leading to a 17.7% increase in the monthly average first year regular premium per agent. Improved operational efficiency and productivity can result in higher net margins.
  • Investment income significantly increased, with a gross investment income rise of 152% year-on-year and a robust net profit increase of 174% year-on-year. This substantial increase in investment income can enhance the company’s overall earnings and profitability.
  • The company maintained a high solvency ratio, with a core solvency ratio of 154.58% and a comprehensive solvency ratio of 211.64%, indicating strong financial stability and risk management, which supports sustainable revenue and earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of HK$23.551 for China Life Insurance based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$31.01, and the most bearish reporting a price target of just HK$14.24.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be CN¥746.6 billion, earnings will come to CN¥67.9 billion, and it would be trading on a PE ratio of 11.0x, assuming you use a discount rate of 6.9%.
  • Given the current share price of HK$23.16, the analyst price target of HK$23.55 is 1.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on China Life Insurance?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives